India, May 28 -- Ipsen S.A. (IPN.PA), a biopharmaceutical company, on Thursday released new late-breaking data strengthening evidence for IQIRVO in treating primary biliary cholangitis, fatigue, and pruritis. The data from the two Phase 3 ELATIVE real-world studies was presented at the European Association for the Study of the Liver (EASL) congress.
Primary biliary cholangitis (PBC) is a rare, autoimmune liver disease where a build-up of bile and toxins causes irreversible fibrosis of the liver, chronic inflammation, and destruction of the bile ducts. The disease can be diagnosed by measuring levels of alkaline phosphatase (ALP), which increases in the blood, leading to symptoms like fatigue.
IQIRVO (elafibranor) is an oral, once-daily pe...